ReviewViruses2026
Emerging Biomarkers and Biotherapies for EBV-Associated Cancers.
Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Epstein-Barr virus (EBV) is an oncogenic human gammaherpesvirus that is prevalent worldwide. Although over 95% of the world's population harbors this pathogen, the vast majority of infections are asymptomatic, largely due to immune system involvement. However, in certain situations, such as when individuals are immunocompromised, the immune system can lose control of EBV suppression, leading to oncogenesis. While standard chemotherapeutic regimens can be effective against some EBV-associated cancers, these treatments can be toxic to some patients, and disease relapse and/or drug resistance can develop. Additionally, no human vaccine currently exists for EBV. In recent years, biotherapy has become a promising avenue for the clinical management of EBV-positive cancers. As early detection is often correlated with a more positive prognosis, identification of reliable EBV biomarkers has also come into focus. In this review, we summarize advancements made over the last five years in immunotherapy use for EBV-positive cancers and in EBV biomarker identification to detect both EBV infection and biotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.